Drugs / G-csf
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03849651 Background | Jan 2019 → Aug 2024 overdue | Hodgkins lymphoma, T-cell and NK-cell neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia +3 | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-csf | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03849651 ↗ |
| Modality | Protein / enzyme biologic | “is a biosynthetic hematopoietic agent that is made using recombinant DNA technology in cultures of Escherichia coli.” NCT03849651 ↗ |
| Route | Intravenous | “subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days” NCT03849651 ↗ |
| Route | Subcutaneous | “subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days” NCT03849651 ↗ |